Long-term Microphysiological Sample Imaging for Evaluation of Polypharmacy in Liver
DeLIVERY develops a microphysiological system to personalize healthcare by investigating drug interactions in elderly patients, aiming to improve treatment outcomes and quality of life.
Projectdetails
Introduction
DeLIVERY aims to build a radically new technology for personalized health care, which provides, for the first time, the possibility to investigate polypharmacy on individual patients.
Background
Polypharmacy is the effect that the many combinations and permutations of drug mixtures, which are typically prescribed to the chronically sick or the elderly population (e.g., painkillers, beta blockers, blood thinners, anti-depressants, and statins), have on the human body.
Polypharmacy is becoming a major issue in the ageing population, as well over 10% of hospital admissions for people over 60 years of age are due to currently unknown interactions of the multiple drugs being prescribed by the specialized physicians and general practitioners routinely visited by the elderly.
Current Challenges
Currently, no single platform exists that can be utilized in a highly parallelized fashion to monitor such effects at the cellular and tissue level.
DeLIVERY's Solution
DeLIVERY will provide an integrated microphysiological system (MPS) culture and microscopic imaging platform specifically for the purpose of maintaining, treating, and long-term imaging of patient-specific cells within their microenvironment.
This MPS platform will allow physicians, biomedical scientists, and researchers to determine the individual response of human tissue biopsies to a combination of multiple drugs.
Impact on Healthcare
DeLIVERY will enable individualized treatment options, providing essential tools towards a better quality of life for older people by allowing improved personalized healthcare.
Novel medicines with the potential to reverse the effects of ageing and non-alcoholic fatty liver disease (NAFLD) will be tested within typical polypharmacy contexts to determine possible interactions, and the DeLIVERY MPS system will be the purpose-built platform to provide this service.
Future Directions
Such a system also requires a paradigm shift in microscopy - away from the single, bulky instrument providing one imaging modality towards compact and modular, yet still high-end, devices.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 3.547.046 |
Totale projectbegroting | € 3.547.046 |
Tijdlijn
Startdatum | 1-5-2022 |
Einddatum | 30-4-2026 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- UNIVERSITAET BIELEFELDpenvoerder
- UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET
- VRIJE UNIVERSITEIT BRUSSEL
- EVANGELISCHES KLINIKUM BETHEL GGMBH
- EXCELITAS PCO GMBH
- CHERRY BIOTECH
- THE HENRYK NIEWODNICZANSKI INSTITUTE OF NUCLEAR PHYSICS, POLISH ACADEMY OF SCIENCES
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Personalised Adaptive MedicineThe PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence. | EIC Pathfinder | € 1.726.876 | 2024 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic DrugsDevelop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery. | EIC Pathfinder | € 2.606.250 | 2022 | Details |
Insight into Drug Distribution and Local Concentration using Multispectral Imaging of Fluorescent Drugs in Inflammatory Bowel DiseasesmsGUIDE aims to enhance IBD treatment through a novel imaging technology that quantifies drug distribution and targets specific cells for personalized medicine and real-time monitoring. | EIC Pathfinder | € 4.027.964 | 2022 | Details |
Personalised Adaptive Medicine
The PERAMEDIC project aims to develop a desktop-sized system for personalized polypill formulation using 3D printing and precise dosing to enhance treatment outcomes and patient adherence.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
On-Demand Bioresorbable OptoElectronic System for In-Vivo and In-Situ Monitoring of Chemotherapeutic Drugs
Develop a bioresorbable chemical sensing system for real-time monitoring of doxorubicin in-vivo, enhancing personalized cancer treatment while eliminating the need for device retrieval surgery.
Insight into Drug Distribution and Local Concentration using Multispectral Imaging of Fluorescent Drugs in Inflammatory Bowel Diseases
msGUIDE aims to enhance IBD treatment through a novel imaging technology that quantifies drug distribution and targets specific cells for personalized medicine and real-time monitoring.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Servicable Digital Biomaker PlatformMS Sherpa voert een haalbaarheidsstudie uit naar een digitaal biomarkerplatform om de effectiviteit van medicijnen in de dagelijkse praktijk te verbeteren en onnodig medicijngebruik te verminderen. | Mkb-innovati... | € 20.000 | 2020 | Details |
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip PlatformsLIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes. | ERC Starting... | € 2.499.318 | 2025 | Details |
IDEFIX Multiorgan toxicity and efficacy test platformCherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions. | EIC Transition | € 2.496.073 | 2022 | Details |
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Servicable Digital Biomaker Platform
MS Sherpa voert een haalbaarheidsstudie uit naar een digitaal biomarkerplatform om de effectiviteit van medicijnen in de dagelijkse praktijk te verbeteren en onnodig medicijngebruik te verminderen.
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip Platforms
LIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes.
IDEFIX Multiorgan toxicity and efficacy test platform
Cherry Biotech's IDEFIX project aims to revolutionize preclinical drug testing by developing a customizable organ-on-chip platform that mimics human multiorgan physiology, enhancing efficacy and toxicity predictions.
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.